(S)-crizotinib reduces gastric cancer growth through oxidative DNA damage and triggers pro-survival akt signal

Gastric cancer (GC), a common gastrointestinal malignancy worldwide, has poor prognosis and frequent recurrence. There is a great need to identify effective therapy for GC. Crizotinib is a multi-targeted, clinically available oral tyrosine kinase inhibitor approved for lung cancer, but its use for t...

Descripción completa

Detalles Bibliográficos
Autores principales: Ji, Jiansong, Chen, Weiqian, Lian, Weishuai, Chen, Ruijie, Yang, Jinqing, Zhang, Qianqian, Weng, Qiaoyou, Khan, Zia, Hu, Jie, Chen, Xi, Zou, Peng, Chen, Xiaoming, Liang, Guang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5981313/
https://www.ncbi.nlm.nih.gov/pubmed/29855474
http://dx.doi.org/10.1038/s41419-018-0667-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5981313/
https://www.ncbi.nlm.nih.gov/pubmed/29855474
http://dx.doi.org/10.1038/s41419-018-0667-x

Ejemplares similares